Difference between revisions of "Inotuzumab ozogamicin (Besponsa)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m (Text replacement - "http://www.chemocare.com/chemotherapy/" to "https://chemocare.com/chemotherapy/") |
||
| Line 13: | Line 13: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://labeling.pfizer.com/ShowLabeling.aspx?id=9503 Inotuzumab ozogamicin (Besponsa) package insert]<ref name="insert"></ref> | *[http://labeling.pfizer.com/ShowLabeling.aspx?id=9503 Inotuzumab ozogamicin (Besponsa) package insert]<ref name="insert"></ref> | ||
| − | *[ | + | *[https://chemocare.com/chemotherapy/drug-info/inotuzumab-ozogamicin.aspx Inotuzumab ozogamicin (Besponsa) patient drug information (Chemocare)]<ref>[https://chemocare.com/chemotherapy/drug-info/inotuzumab-ozogamicin.aspx Inotuzumab ozogamicin (Besponsa) patient drug information (Chemocare)]</ref> |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Revision as of 00:24, 1 January 2022
General information
Class/mechanism: Antibody targeting CD22, conjugated with a cytotoxic, antitumor antibiotic (calicheamicin). Inotuzumab demonstrates a dose-dependent cytotoxicity both in vitro and in vivo. [1][2][3][4]
Route: IV
Extravasation: No information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Diseases for which it is used
Patient drug information
- Inotuzumab ozogamicin (Besponsa) package insert[1]
- Inotuzumab ozogamicin (Besponsa) patient drug information (Chemocare)[5]
History of changes in FDA indication
- 8/17/2017: FDA approved for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). (Based on INO-VATE ALL)
Also known as
- Code name: CMC-544
- Brand name: Besponsa